Global Autoimmune Partnering 2012-2018: Deal trends, players and financials
|発行||Current Partnering, a division of Wildwood Ventures Limited||商品コード||325528|
|出版日||ページ情報||英文 700+ Pages
|自己免疫関連の提携条件と契約 Global Autoimmune Partnering 2012-2018: Deal trends, players and financials|
|出版日: 2018年02月01日||ページ情報: 英文 700+ Pages||
当レポートでは、自己免疫関連の提携条件と契約について調査分析し、提携取引の動向、平均取引条件、提携契約構造、提携契約書類、取引高 (金額別) 、最も積極的な契約企業などについて、体系的な情報を提供しています。
The ‘Global Autoimmune Partnering 2012-2018: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies.
‘Global Autoimmune Partnering 2012 to 2018’ provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Autoimmune deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Autoimmune deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2012. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.
‘Global Autoimmune Partnering 2012 to 2018’ provides the reader with the following key benefits: